|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q91737474
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000047.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q91737474
|
|
024
|
|
|
‡a
0000-0003-4654-1390
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q91737474
|
|
100
|
0 |
|
‡a
Richard G McWilliams
‡c
researcher (ORCID 0000-0003-4654-1390)
‡9
en
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Richard G McWilliams
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study
|
|
909
|
|
|
‡a
(orcid) 0000000346541390
‡9
1
|
|
919
|
|
|
‡a
observationalstudyontheincidenceofnephrogenicsystemicfibrosisinpatientswithrenalimpairmentfollowinggadoteratemeglumineadministrationthenssafestudy
‡A
Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
LC|no2020123391
|
|
996
|
|
|
‡2
DNB|1158570104
|
|
996
|
|
|
‡2
BNF|16620083
|
|
996
|
|
|
‡2
BNF|15730918
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
